Receive our newsletter – data, insights and analysis delivered to you
  1. News
January 25, 2017

Arsanis begins dosing patients in Phase II trial of ASN100 to prevent S. aureus pneumonia

Bio-pharmaceutical company Arsanis has begun dosing patients in a Phase II clinical trial of ASN100 to treat Staphylococcus aureus (S.aureus) pneumonia in high-risk, mechanically ventilated patients.

Bio-pharmaceutical company Arsanis has begun dosing patients in a Phase II clinical trial of ASN100 to treat Staphylococcus aureus (S.aureus) pneumonia in high-risk, mechanically ventilated patients.

ASN100 is developed with a combination of two fully human monoclonal antibodies ASN-1 and ASN-2, to neutralise six S. aureus cytotoxins associated with pneumonia pathogenesis.

The Phase II study will evaluate the mechanically ventilated patients at high risk for S. aureus pneumonia for up to 21 days after dosing.

The patients will be randomised to receive a single dose of ASN100 or placebo and up to 350 individuals will be enrolled across 60 sites.

Arsanis chief executive officer Rene Russo said: “We believe targeted, precision monoclonal antibody therapies are advantageous for the prevention and treatment of infectious diseases while avoiding antibiotic resistance.

Content from our partners
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success
Patient-centric pharma logistics: How CRYOPDP delivers hope worldwide

"ASN100 aligns with the medical and scientific field’s desire and needs to move from broad-spectrum antibiotics toward prevention in patients that are at high risk of developing infection.

"Initiating the ASN100 Phase 2 study brings us closer to potentially providing this targeted solution for patients who are especially vulnerable to developing S. aureus pneumonia."

“Initiating the ASN100 Phase 2 study brings us closer to potentially providing this targeted solution for patients who are especially vulnerable to developing S. aureus pneumonia.”

ASN-1 is designed to neutralise S. aureus toxin alpha-hemolysin (Hla) along with four leukocidins of the bacteria, which disintegrate human phagocytic (immune) cells.

ASN-2 inactivates leukocidin LukGH, which causes lysis of human phagocytes.

The firm claimed that the completed Phase I study evaluated tolerability and pharmacokinetics of the drug in healthy volunteers and the safety profile was found to be consistent with fully human monoclonal antibodies.


Image: Scanning electron micrograph of Staphylococcus aureus bacteria. Photo: courtesy of Janice Haney Carr/Wikipedia.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU